Curtis statement at EPW subcommittee hearing on chemical regulation
The Breakdown
With U.S. innovation in chemical manufacturing under pressure, Senate leadership recently examined the regulatory environment governing both new and existing chemicals. In testimony at a key subcommittee hearing, leaders from Huntsman Corporation and Boeing illustrated the growing tension between the need for accelerated material innovation—crucial for U.S. industrial competitiveness and sustainability—and a regulatory system that often lags behind industry pace. Both upstream (chemical manufacturers) and downstream (OEMs, such as aerospace) players emphasized that regulatory ambiguity and approval delays jeopardize not only their investment, but also the broader supply chain and the end users who rely on next-generation chemistries for safety and performance.
Analyst View
The specialized chemical and polymer sector is fueled by a relentless demand for advanced materials that support cleaner, lighter, and safer products across automotive, aerospace, and healthcare markets. There is an unmistakable market pull for innovation in these fields—but the path to commercialization is increasingly constrained by regulatory inertia. As both the voice of material creators and demanding end-users made clear, current approval processes are not keeping pace with scientific and technological advancements, introducing significant uncertainty to business planning and capital allocation.
The risk extends beyond R&D into full value chain disruption. Suppliers risk seeing transformational projects shelved, while OEMs may be forced to delay or forego the integration of critical, safety- and sustainability-enhancing chemistries. As regulatory bodies struggle to coordinate and update their frameworks, organizations encounter not only resource drag but also heightened competitive threats—from both international rivals with swifter pathways and the diffusion of manufacturing activity offshore. Leaders must recognize that regulatory pace now shapes the global context for growth, production, and the viability of U.S.-based innovation leadership.
Navigating the Signals
For C-suites in specialty chemicals and downstream manufacturing, agile strategic response is essential. The pressure point is a complex, changing regulatory environment. Cross-functional teams—especially regulatory affairs, innovation, and commercial management—must proactively seek transparency in approval timelines and regulatory alignment. Leading organizations are re-evaluating portfolio strategies, supplier relationships, and innovation bets with a critical eye on policy developments at both the federal and agency level.
This moment raises pivotal questions internally: Are your R&D investments protected against shifting approval criteria? Do you have direct engagement and scenario planning with regulators built into your go-to-market strategy? Are your value chain partners aligned on risk-sharing if approvals are stalled? Now is the time to challenge inertia and reinforce linkages across the ecosystem so that innovation investment is not siloed, but resilient to these market fluctuations.
What’s Next?
Breakthrough Marketing Technology helps organizations outmaneuver regulatory-induced business risk by:
- Quantifying the impact of changing policy on product launch timelines and growth forecasts
- Mapping decision points and building scenario-based playbooks for regulatory action or delay
- Aligning cross-functional and cross-organizational teams to strengthen the collective voice and advocacy with oversight bodies
- Equipping leadership with strategic early-warning systems that track regulatory and market signals in real time
With custom market clarity solutions, leadership teams can convert policy uncertainty into strategic foresight and sustainable competitive edge.
Source
Understand Your Risk. Seize Your Opportunity.
Take the Breakthrough Market Uncertainty Assessment Guide to pinpoint what’s holding your growth back, and what can accelerate it.
